Results 131 to 140 of about 205,861 (285)

Most costly and prevalent reasons for hospitalization in children with medical complexity in Ontario, Canada

open access: yesJournal of Hospital Medicine, EarlyView.
Abstract Background and Objectives Children with medical complexity (CMC) have chronic health conditions often associated with functional limitations. CMC comprise 1%–5% of the pediatric population. In Canada, their care accounts for one‐third of pediatric health spending.
Erin Hessey   +25 more
wiley   +1 more source

Liver disease in Shwachman‐Diamond syndrome: A comprehensive characterization across the age spectrum

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Shwachman‐Diamond syndrome (SDS) is an inherited bone marrow failure disorder, and its hepatic phenotype is poorly defined. Our objective was to systematically characterize the prevalence, features, and outcomes of liver injury in a multicenter SDS cohort. Methods Retrospective registry study of 171 patients with biallelic Shwachman‐
Jane Koo   +16 more
wiley   +1 more source

NEUTROPENIA FEBRIL EN PEDIATRIA Febrile Neutropenia in Pedriatrics

open access: yesInfectio, 2008
La neutropenia febril es una condición frecuente en los pacientes pediátricos con cáncer. En el momento en que se hace este diagnóstico, el médico debe conducir una entrevista y un examen físico rigurosos, obtener cultivos e iniciar antibióticos para ...
Pio Lopez, Eduardo Lopez
doaj  

Hematological manifestation of Pediatric Systemic Lupus Erythematosus (SLE) – A single centered cross-sectional study

open access: yesJournal of Family Medicine and Primary Care
Introduction: Systemic lupus erythematosus (SLE), the commonest type of lupus, is an autoimmune multisystemic disorder that can affect any organ system of the body, especially blood vessels and connective tissues, causing widespread inflammation ...
Md Rakibul Hassan   +4 more
doaj   +1 more source

Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment [PDF]

open access: yes, 2017
A Rai   +30 more
core   +3 more sources

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

open access: yesJPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan   +2 more
wiley   +1 more source

A Single Center Survey of Patients With Congenital Neutropenia: Report From Northwestern Iran

open access: yesActa Medica Iranica, 2018
Neutropenia is characterized by a decrease in circulating neutrophil counts and consequent infections.  The present study was performed so as to describe the clinical and laboratory findings of patients with congenital neutropenia in northwestern Iran ...
Mahnaz Sadeghi-Shabestari   +4 more
doaj  

Ceftazidime–Avibactam Improves Outcomes in High-Risk Neutropenic Patients with Klebsiella pneumoniae Carbapenemase-Producing Enterobacterales Bacteremia

open access: yesMicroorganisms
Few studies have evaluated the efficacy of ceftazidime–avibactam (CA) for Klebsiella pneumoniae carbapenemase-producing Enterobacterales bacteremia (KPC-PEB) in high-risk neutropenic patients. This is a prospective multicenter observational study in high-
Fabián Herrera   +21 more
doaj   +1 more source

Differentiation Syndrome and Sweet Syndrome‐Like Overlap Following Venetoclax–Azacytidine and G‐CSF Therapy

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Differentiation syndrome (DS) and Sweet syndrome (SS) are inflammatory complications mediated by cytokine dysregulation, classically associated with therapies that promote myeloid differentiation or cytokine release. While DS has been primarily linked to all‐trans retinoic acid (ATRA) and IDH inhibitors, recent evidence suggests that ...
Katerina Grafanaki   +6 more
wiley   +1 more source

An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease

open access: yesMovement Disorders, EarlyView.
Complement activation is implicated in Huntington's disease; ANX005 is a potent inhibitor of component C1q. ANX005 exhibited a generally manageable safety profile with rapid reduction in C1q in the cerebrospinal fluid. Functional ability on composite Unified Huntington's Disease Rating Scale and total functional capacity was maintained, with potential ...
Rajeev Kumar   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy